 Cancer Vaccines
"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 | | 1998 | 3 | 2 | 5 | | 2000 | 2 | 1 | 3 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 2 | 3 | | 2003 | 3 | 2 | 5 | | 2004 | 5 | 1 | 6 | | 2005 | 5 | 1 | 6 | | 2006 | 6 | 2 | 8 | | 2007 | 6 | 0 | 6 | | 2008 | 4 | 6 | 10 | | 2009 | 3 | 1 | 4 | | 2010 | 7 | 3 | 10 | | 2011 | 2 | 1 | 3 | | 2012 | 6 | 2 | 8 | | 2013 | 7 | 2 | 9 | | 2014 | 3 | 0 | 3 | | 2016 | 3 | 0 | 3 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 3 | 5 | | 2019 | 3 | 3 | 6 | | 2020 | 5 | 1 | 6 | | 2021 | 1 | 2 | 3 | | 2022 | 3 | 0 | 3 | | 2023 | 1 | 0 | 1 | | 2024 | 1 | 1 | 2 | | 2025 | 4 | 0 | 4 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Zeng Y, Xu J, Wang J, Xue L, Liu J, Geisler HC, Ma X, Melamed JR, Shi Q, Padilla MS, Luo Z, Zhu J, Thatte AS, Figueroa-Espada CG, Ang MJY, Murray AM, Yamagata HM, Kim D, Metzloff AE, Weissman D, Mitchell MJ. mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity. Proc Natl Acad Sci U S A. 2026 Jul 14; 123(28):e2525718123.
-
Bansal A, Stoffel EM, Lim R, Stanich PP, Patel SG, Burke CA, Hall MJ, Singh A, Boardman LA, Samadder NJ, Ballestar V, Muller C, Scott AJ, Benante KA, Xu Y, Eickhoff J, Hyun M, Zaborek J, Aquila L, Umar A, Szabo E, Della'Zanna G, Richmond E, Bengtson L, Schlom J, Donahue RN, Toney NJ, Horn LA, Palena C, Gulley JL, Samaddar S, Moore DF, Sharma P, Madan R, Hurley KE, Soon-Shiong P, Gabitzsch E, Sender L, Brenner D, Schuetze S, Djuric Z, Barroilhet LM, Thompson P, Bauman J, Khan SA, Vilar E. Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). Front Immunol. 2026; 17:1809281.
-
Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Eur J Cancer. 2026 Jan 17; 233:116162.
-
Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, O'Reilly EM. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025 Nov; 31(11):3648-3653.
-
Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, Yamashita T, Kuroda A, Nomura S, Akita H, Itaka K, Kodama T, Kakimi K. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. 2025 09; 28(5):825-836.
-
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025 08 20; 43(24):2671-2678.
-
Mason NJ, Selmic L, Ruple A, London CA, Barber L, Weishaar K, Perry JA, Mahoney J, Flesner B, Bryan JN, Willcox JL, Burton JH, Vail DM, Kisseberth WC, Balkman CE, McCleary-Wheeler AL, Curran KM, Leeper H, Woods JP, Mutsaers AJ, Higginbotham ML, Wouda RM, Wilson-Robles H, Dervisis N, Saba C, MacDonald-Dickinson VS, Hess PR, Cherukuri A, Rotolo A, Beck JA, Patkar S, Mazcko C, LeBlanc AK. Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2. Mol Ther. 2025 04 02; 33(4):1674-1686.
-
Zhang Y, Liu X, Shen T, Wang Q, Zhou S, Yang S, Liao S, Su T, Mei L, Zhang B, Huynh K, Xie L, Guo Y, Guo C, Tyc KM, Qu X, Wang XY, Liu J, Zhu G. Small circular RNAs as vaccines for cancer immunotherapy. Nat Biomed Eng. 2025 Feb; 9(2):249-267.
-
Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2025 03 15; 121(4):930-941.
-
Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ. Enhancing in situ cancer vaccines using delivery technologies. Nat Rev Drug Discov. 2024 08; 23(8):607-625.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|